1-3 of 3
Chris Rovaldi
Close
Sort by
Journal Articles

Modulation of TGF-β Superfamily Signaling to Treat Myelofibrosis and Mitigate JAK Inhibitor Toxicity: A Report on the Phase 2 Study of Ker-050 in Participants with Myelofibrosis

Claire Harrison, Shuh Ying Tan, David M Ross, George Kannourakis, Allie McGinty, Wei Feng, Ying Jiang, Christine Graham, Chris Rovaldi, Simon Cooper, Jen L. Salstrom
Journal: Blood
Blood (2022) 140 (Supplement 1): 9702–9703.
https://doi.org/10.1182/blood-2022-162761
Published: 2022
Journal Articles

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

David M Ross, Alejandro Arbelaez, Lynette C.Y. Chee, Chun Yew Fong, Devendra Hiwase, George Kannourakis, John Kwan, James Liang, Anish Puliyayil, Hannah Rose, Shuhying Tan, Tse-Chieh Teh, David Alan Westerman, Joel Wight, Chris Rovaldi, Elissa M. Furutani, Adrienne Gaggi, Ying Jiang, Jenn Lachey, Harveen Dhillon Natarajan, Claudia Ordonez
Journal: Blood
Blood (2021) 138 (Supplement 1): 3675.
https://doi.org/10.1182/blood-2021-147335
Published: 2021
Journal Articles

Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Philipp Kiewe, Ulrich Germing, MD, Katharina S. Götze, MD, Karin Mayer, MD, Markus P. Radsak, MD, Thomas Wolff, MD, Joerg Chromik, Dawn Wilson, Xiaosha Zhang, PhD, Chris Rovaldi, MSc, Abderrahmane Laadem, MD, Matthew Leigh Sherman, MD, Kenneth Morris Attie, MD, Joseph Reynolds, PhD, Peter Guest Linde, MD, Aristoteles Giagounidis, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2982.
https://doi.org/10.1182/blood.V130.Suppl_1.2982.2982
Published: 2017